Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Dietary Measures to Prevent Sudden Unexpected Death in Epilepsy—Reply

Dietary Measures to Prevent Sudden Unexpected Death in Epilepsy—Reply Letters In Reply We appreciate the interest and comments of Palma et al prevent death), but we may be able to classify potential risk regardingourrecentreviewabouttheonsetofsynucleinopathies. factors or determine the pathophysiological mechanisms that Thereviewwasbasedonepidemiologicalevidence.Notably,there are responsible for SUDEP. have not been sufficient epidemiologic data that examine some Regarding administering preventive measures properly, ω-3 of the early manifestations or symptoms for some aspects of fatty acid supplementation for individuals with epilepsy is still synucleinopathies. As an example, the prospective study per- neglected by epileptologists. Why? For more than a decade, a formed by the Autonomic Disorders Consortium on the natural possible neuroprotective and cardioprotective role of ω-3 fatty 2 3 history of pure autonomic failure was based on 100 patients. acids has been demonstrated. Briefly, translational studies have Although the sample size is large for a pure autonomic failure demonstrated that supplementation with ω-3 fatty acids may study, it is a relatively small number when compared with larger reduce seizures and seizure-associated cardiac arrhythmias, 3,4 population-basedepidemiologycohorts.Likewise,orthostatichy- and as a result SUDEP. Even so, why not prescribe ω-3 fatty potension is one of the most important signs of dysautonomia in acids to patients? Is there a need for more randomized clinical synucleinopathies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Dietary Measures to Prevent Sudden Unexpected Death in Epilepsy—Reply

Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/dietary-measures-to-prevent-sudden-unexpected-death-in-epilepsy-reply-gISYtP0ZcK

References (5)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/jamaneurol.2018.2254
Publisher site
See Article on Publisher Site

Abstract

Letters In Reply We appreciate the interest and comments of Palma et al prevent death), but we may be able to classify potential risk regardingourrecentreviewabouttheonsetofsynucleinopathies. factors or determine the pathophysiological mechanisms that Thereviewwasbasedonepidemiologicalevidence.Notably,there are responsible for SUDEP. have not been sufficient epidemiologic data that examine some Regarding administering preventive measures properly, ω-3 of the early manifestations or symptoms for some aspects of fatty acid supplementation for individuals with epilepsy is still synucleinopathies. As an example, the prospective study per- neglected by epileptologists. Why? For more than a decade, a formed by the Autonomic Disorders Consortium on the natural possible neuroprotective and cardioprotective role of ω-3 fatty 2 3 history of pure autonomic failure was based on 100 patients. acids has been demonstrated. Briefly, translational studies have Although the sample size is large for a pure autonomic failure demonstrated that supplementation with ω-3 fatty acids may study, it is a relatively small number when compared with larger reduce seizures and seizure-associated cardiac arrhythmias, 3,4 population-basedepidemiologycohorts.Likewise,orthostatichy- and as a result SUDEP. Even so, why not prescribe ω-3 fatty potension is one of the most important signs of dysautonomia in acids to patients? Is there a need for more randomized clinical synucleinopathies.

Journal

JAMA Neurology – American Medical Association

Published: Sep 13, 2018

There are no references for this article.